Angion Biomedica Corp Aktie News

BOSTON, 2. Juli 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) („Elicio“ oder das „Unternehmen“), ein im klinischen Stadium befindliches Biotechnologieunternehmen, das Next‑Generation-Immuntherapien für KRAS-getriebene Krebserkrankungen entwickelt, gab heute bekannt, dass es eine endgültige Wertpapierkaufvereinbarung mitgeführt von zwei neuen institutionellen Kerninvestoren m...

BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company was added to the Russell 2000® and Russell 3000® Indexes, effective after the U.S. market close on June 26, 2026, as part of the 2026 Russell ind...

100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapy Complete responses (“CRs”) are rarely (0-8%) observed in metastatic pancreatic cancer in published studies evaluating chemotherapy-, checkpoint inhibitor-, and RAS inhibitor-based regime...

Elicio Therapeutics reported Q1 2026 results showing a widening net loss and zero revenue days before its lead clinical program failed -- investors who bought ELTX lost 72.5% in a single session. NEW YORK, June 16, 2026 /PRNewswire/ -- Elicio Therapeutics (NASDAQ: ELTX) investors lost approximately 72.53% of their investment value today after the Company disclosed that its Phase 2 AMPLIFY-7P st...

Elicio Therapeutics shares fell about 73% in early trading on Monday after the biotech firm's pancreatic cancer therapy failed to significantly extend the time ​patients lived without their disease returning, missing the main goal of ‌a mid-stage study.

BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for mKRAS-driven cancers, today reported results from its randomized Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with adjuvant mKRAS-driven pancreatic ductal adenocarcinoma (“PDAC”) followi...

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of a peer-reviewed manuscript in Science Advances, published by the American Association for the Advancement of Science, describing a serie...

In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), the event-driven primary disease-free survival (“DFS”) analysis is anticipated mid-year 2026 The Company raised net proceeds of approximately $8.0 million in Q1 2026 and an additional $5.0 million in Q2 2026 to date, for aggregate net proceeds of approximately $13.0 million,...